Drug Profile
Research programme: neuregulins - Acorda Therapeutics
Alternative Names: Neuregulin 2 protein; NRG-2Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Harvard University
- Developer Acorda Therapeutics
- Class Nerve tissue proteins; Neuregulins
- Mechanism of Action Epidermal growth factor receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Heart failure; Neurological disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Heart-failure in USA (SC)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Neurological-disorders in USA (SC)
- 28 Feb 2012 Acorda Therapeutics' neuregulins research programme is still in preclinical development in the US